[e-med] Article OMS sur l'impact des brevets sur la santé publique

["Carinne Bruneton" <remed@remed.org>]

[Vous pouvez télécharger ci-dessous le dernier numéro des informations OMS 
sur les médicaments
http://www.who.int/druginformation/vol19num3_2005/DI19-3.pdf
A noter page 236 l'article intéressant sur l'accès aux médicaments intitulé 
"Intellectual property protection: impact on public health". CB]

WHO Drug Information
Vol 19, No. 3, 2005

Sommaire
Contents
World Health Organization
Personal Perspectives
Unfinished business: clinical pharmacology and world health 201

Safety and Efficacy Issues
Transdermal fentanyl: abuse by adolescents 207
Safety of fentanyl transdermal patches 207
Rosiglitazone: decreased high-density
lipoprotein cholesterol 208
Ibuprofen: Stevens-Johnson syndrome 208
Stringent conditions for COX-2 inhibitors 209
Sildenafil, tadalafil and vardenafil: eye
problems reported 209
Nesiritide: safety report and measures 210
Mifepristone, sepsis and blood infection 211
Mifepristone: revised safety information 211
Suicidality with SSRIs in adults 211
Ezetimibe and muscle disorders 212
Pathological gambling with cabergoline 212
Icodextrin peritoneal dialysis solution: falsely
elevated blood glucose readings 213
New requirements for pseudoephedrine
products 213
Efalizumab: warning of thrombocytopenia 214
Antiretrovirals: HIV, hepatic impairment
and HBV/HCV 214

Herbal Medicines
Monograph for cultivation of herbal
antimalarial: Artemisia annua 215
Ayurvedic medicines and heavy metals 215
National policy on regulation of herbal
medicines 216
Regulatory guidelines for complementary
medicines 216

Regulatory Action and News
Hydromorphone extended release
suspended 217
New drug safety initiative 217
Deregistration of thioridazine 217
Caution on self medication 218
European marketing authorizations 218
Tigecycline: first-in-class antibiotic approved 219

Essential Medicines
Highlights of the 14th Model List of
Essential Medicines 220
Methadone and buprenorphine 220
Mifepristone with misoprostol 220
WHO Model List of Essential Medicines 222

Access to Medicines
Intellectual property protection: impact on
public health 236

The International Pharmacopoeia
International Pharmacopoeia: fourth edition
in development 242

Recommended International
Nonproprietary Names:
List 54 243